Ligands of Immunopharmacology

ODN M362, a class C oligodeoxynucleotide, is a TLR-9 agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosisForm:SolidIC50&amp Target:TLR9

ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9 , AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the

OncoFAP is an ultra-high-affinity ligand of fibroblast activation protein (FAP) for targeting applications with pan-tumoral potential.Form:Solid

OncoFAP is an ultra-high-affinity ligand of fibroblast activation protein (FAP) for targeting applications with pan-tumoral potential.Form:Solid

Oxaprozin-d 4 is the deuterium labeled Oxaprozin, which is a non-steroidal anti-inflammatory agent (NSAID).Appearance:SolidBiological Activity:Oxaprozin-d 4 is the deuterium labeled Oxaprozin, which is a non-steroidal anti-inflammatory agent (NSAID).

PD-1-IN-17 is a programmed cell death-1 ( PD-1 ) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nMForm:SolidIC50&amp Target:PD-1

PD-1-IN-17 is a programmed cell death-1 ( PD-1 ) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nMForm:SolidIC50&amp Target:PD-1

PD-1-IN-17 is a programmed cell death-1 ( PD-1 ) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nMForm:SolidIC50&amp Target:PD-1

PD-1-IN-17 is a programmed cell death-1 ( PD-1 ) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nMForm:SolidIC50&amp Target:PD-1

PD-1-IN-17 is a programmed cell death-1 ( PD-1 ) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nMForm:SolidIC50&amp Target:PD-1

PD-1-IN-17 is a programmed cell death-1 ( PD-1 ) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nMIC50&amp Target:PD-1

PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.In VivoPD-1-IN-24 (compound 1, 15mg/kg, PO, BID) exhibits TGI(%) of 19.96% in the subcutaneous 4T1 murine breast cancer model in BALB/c mice . PD-1-IN-24 (compound 1, 15mg/kg, PO, BID)